A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure.

Trial Profile

A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Aliskiren; Furosemide
  • Indications Essential hypertension; Heart failure
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 May 2012 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
    • 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Apr 2011 Lithuania added as study country
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top